Clinical Trial Update: Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing LV5FU2 versus FOLFOX in curatively resected, node-positive esophageal squamous cell carcinoma. The trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• FOLFOX
• LV5FU2 (leucovorin + fluorouracil (5-FU))

Snippet

Sponsor: Samsung Medical Center | Conditions: Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN